The FDA classifies BPC-157 as a Category 2 bulk drug substance meaning its not FDA-approved for human use and has been flagged as potentially presenting safety risks in unregulated compounding

"GLP-1 receptor agonists should be prescribed alongside structured lifestyle interventionsspecifically resistance training at least 3 times weekly, 150 minutes of moderate-intensity aerobic exercise weekly, and nutrient-dense dietary counselingto preserve muscle and bone mass, optimize weight loss, and improve cardiometabolic outcomes." "Protein intake alone is insufficient without structured resistance training, and combination therapy produces superior metabolic benefits compared to pharmacotherapy alone, including better preservation of lean mass, improved cardiorespiratory fitness, and prevention of GLP-1-associated increases in resting heart rate." I wrote earlier about this balance in a piece called The central idea still holds: GLP-1 medications can improve metabolic markers dramatically, but without strength training and adequate nutrition, people may lose meaningful lean mass
They protect your kidneys, your liver, and your cardiovascular system
Presented for research literature review only Mettang T et al
Bolanos JP, Herrero-Mendez A, Fernandez-Fernandez S, Almeida A
10.1385/JMN:18:1-2:07 177